S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis) - Part 2: Supportive therapy of EN in the acute and post-acute stages.

Drug reaction Lyell syndrome Stevens‐Johnson syndrome epidermal necrolysis toxic epidermal necrolysis

Journal

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
ISSN: 1610-0387
Titre abrégé: J Dtsch Dermatol Ges
Pays: Germany
ID NLM: 101164708

Informations de publication

Date de publication:
17 Oct 2024
Historique:
received: 12 06 2024
accepted: 18 06 2024
medline: 17 10 2024
pubmed: 17 10 2024
entrez: 17 10 2024
Statut: aheadofprint

Résumé

Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are rare, predominantly drug-induced, acute life-threatening diseases of skin and mucosae. SJS and TEN are nowadays considered as variants of one disease entity with varying degrees of severity called epidermal necrolysis (EN). EN is associated with high morbidity and mortality and constitutes a major disease burden for affected patients. The guideline "Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis)" was developed under systematic consideration of existing scientific literature and in a formal consensus process according to regulations issued by the Association of Scientific Medical Societies in Germany (AWMF) to establish an evidence-based framework to support clinical decision-making. The interdisciplinary guideline commission consisted of representatives from various specialist societies and of patient representatives. The guideline is aimed at specialists in the fields of dermatology, ophthalmology, plastic surgery, intensive care, and pediatrics in hospitals and offices, as well as other medical specialties involved in the diagnosis and treatment of EN. The guideline is also aimed at patients, their relatives, insurance funds, and policymakers. The second part is concerned with the topics of supportive therapy in the acute phase of EN and outpatient follow-up treatment.

Identifiants

DOI: 10.1111/ddg.15516 PMID: 39417754
pubmed: 39417754
doi: 10.1111/ddg.15516
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024 The Author(s). Journal der Deutschen Dermatologischen Gesellschaft published by Wiley‐VCH GmbH on behalf of Deutsche Dermatologische Gesellschaft.

Références

Kramer A, Dissemond J, Kim S, et al. Consensus on Wound Antisepsis: Update 2018. Skin Pharmacol Physiol. 2018;31:28‐58.
Wiegand C, Abel M, Ruth P, Hipler UC. HaCaT keratinocytes in co‐culture with Staphylococcus aureus can be protected from bacterial damage by polihexanide. Wound Repair Regen. 2009;17:730‐738.
World Health Organization. Prevention and management of wound infection: guidance from WHO's Department of Violence and Injury Prevention and Disability and the Department of Essential Health Technologies. 2008.
Pfurtscheller K, Zobel G, Roedl S, Trop M. Use of Suprathel dressing in a young infant with TEN. Pediatr Dermatol. 2008;25:541‐543.
Lindford AJ, Kaartinen IS, Virolainen S, Vuola J. Comparison of Suprathel(R) and allograft skin in the treatment of a severe case of toxic epidermal necrolysis. Burns. 2011;37:e67‐e72.
Boorboor P, Vogt PM, Bechara FG, et al. Toxic epidermal necrolysis: use of Biobrane or skin coverage reduces pain, improves mobilisation and decreases infection in elderly patients. Burns. 2008;34:487‐492.
Young JB, Gondek SP, Troche M, et al. The use of porcine xenografts in patients with toxic epidermal necrolysis. Burns. 2016;42(8):1728‐1733.
Gerding RL, Imbembo AL, Fratianne RB. Biosynthetic skin substitute vs. 1 % silver sulfadiazine for treatment of inpatient partial‐thickness thermal burns. J Trauma. 1988;28:1265‐1269.
Gerding RL, Emerman CL, Effron D, et al. Outpatient management of partial‐thickness burns: Biobrane versus 1 % silver sulfadiazine. Ann Emerg Med. 1990;19:121‐124.
Wasiak J, Cleland H, Campbell F, Spinks A. Dressings for superficial and partial thickness burns. Cochrane Database Syst Rev. 2013;2013:Cd002106.
Grade S, Eberhard J, Wagener P, et al. Therapeutic Window of Ligand‐Free Silver Nanoparticles in Agar‐Embedded and Colloidal State: In Vitro Bactericidal Effects and Cytotoxicity. Advanced Engineering Materials. 2012;14:B231‐B239.
Cutting K, White R, Edmonds M. The safety and efficacy of dressings with silver – addressing clinical concerns. Int Wound J. 2007;4:177‐184.
Rayman G, Rayman A, Baker NR, et al. Sustained silver‐releasing dressing in the treatment of diabetic foot ulcers. Br J Nurs. 2005;14:109‐114.
Das KK, Khondokar S, Rahman A, Chakraborty A. Unidentified drugs in traditional medications causing toxic epidermal necrolysis: A developing country experience. Int J Dermatol. 2014;53:510‐515.
Huang SH, Lin CH, Chang KP, et al. Clinical evaluation comparing the efficacy of aquacel Ag with vaseline gauze versus 1 % silver sulfadiazine cream in toxic epidermal necrolysis. Adv Skin Wound Care. 2014;27:210‐215.
Wyatt D, McGowan DN, Najarian MP. Comparison of a hydrocolloid dressing and silver sulfadiazine cream in the outpatient management of second‐degree burns. J Trauma. 1990;30:857‐865.
Barajas‐Nava LA, Lopez‐Alcalde J, Roque i Figuls M, et al. Antibiotic prophylaxis for preventing burn wound infection. Cochrane Database Syst Rev. 2013;CD008738.
Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol. 1987;123:1160‐1165.
Mockenhaupt M, Roujeau J‐C. Epidermal Necrolysis (Stevens‐Johnson Syndrome and Toxic Epidermal Necrolysis). In: Kang S, Amagai M, Bruckner AL, et al, eds. Fitzpatrick's Dermatology, 9e. McGraw‐Hill Education; 2019.
Creamer D, Walsh SA, Dziewulski P, et al. U.K. guidelines for the management of Stevens‐Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol. 2016;174:1194‐1227.
Power WJ, Ghoraishi M, Merayo‐Lloves J, et al. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens‐Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology. 1995;102:1669‐1676.
Chang YS, Huang FC, Tseng SH, et al. Erythema multiforme, Stevens‐Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. Cornea. 2007;26:123‐129.
Gregory DG. New Grading System and Treatment Guidelines for the Acute Ocular Manifestations of Stevens‐Johnson Syndrome. Ophthalmology. 2016;123:1653‐1658.
Sotozono C, Ueta M, Nakatani E, et al. Predictive Factors Associated With Acute Ocular Involvement in Stevens‐Johnson Syndrome and Toxic Epidermal Necrolysis. Am J Ophthalmol. 2015;160:228‐237 e2.
Bagga B, Motukupally SR, Mohamed A. Microbial keratitis in Stevens‐Johnson syndrome: Clinical and microbiological profile. Ocul Surf. 2018;16:454‐457.
Sharma N, Venugopal R, Singhal D, et al. Microbial Keratitis in Stevens‐Johnson Syndrome: A Prospective Study. Cornea. 2019;38:938‐942.
Sharma N, Thenarasun SA, Kaur M, et al. Adjuvant Role of Amniotic Membrane Transplantation in Acute Ocular Stevens‐Johnson Syndrome: A Randomized Control Trial. Ophthalmology. 2016;123:484‐491.
Shanbhag SS, Rashad R, Chodosh J, Saeed HN. Long‐Term Effect of a Treatment Protocol for Acute Ocular Involvement in Stevens‐Johnson Syndrome/Toxic Epidermal Necrolysis. Am J Ophthalmol. 2019;208:331‐341.
Meneux E, Paniel BJ, Pouget F, et al. Vulvovaginal sequelae in toxic epidermal necrolysis. J Reprod Med. 1997;42:153‐156.
Meneux E, Wolkenstein P, Haddad B, et al. Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases. Obstet Gynecol. 1998;91:283‐287.
Van Batavia JP, Chu DI, Long CJ, et al. Genitourinary involvement and management in children with Stevens‐Johnson syndrome and toxic epidermal necrolysis. J Pediatr Urol. 2017;13:490 e1‐490 e7.
O'Brien KF, Bradley SE, Mitchell CM, et al. Vulvovaginal manifestations in Stevens‐Johnson syndrome and toxic epidermal necrolysis: Prevention and treatment. J Am Acad Dermatol. 2021;85:523‐528.
Seminario‐Vidal L, Kroshinsky D, Malachowski SJ, et al. Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens‐Johnson syndrome/toxic epidermal necrolysis in adults. J Am Acad Dermatol. 2020;82:1553‐1567.
Petukhova TA, Maverakis E, Ho B, Sharon VR. Urogynecologic complications in Stevens‐Johnson syndrome and toxic epidermal necrolysis: Presentation of a case and recommendations for management. JAAD Case Rep. 2016;2:202‐205.
Lerch M, Mainetti C, Terziroli Beretta‐Piccoli B, Harr T. Current Perspectives on Stevens‐Johnson Syndrome and Toxic Epidermal Necrolysis. Clin Rev Allergy Immunol. 2018;54:147‐176.
Chantaphakul H, Sanon T, Klaewsongkram J. Clinical characteristics and treatment outcome of Stevens‐Johnson syndrome and toxic epidermal necrolysis. Exp Ther Med. 2015;10:519‐524.
DenAdel MA, Hendrickson SE, Fuchs E. Stevens Johnson Syndrome: Past, Present, and Future Directions Gynecologic Manifestations and Management in SJS/TEN. Front Med (Lausanne). 2022;9:874445.
Lee HY, Walsh SA, Creamer D. Long‐term complications of Stevens‐Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow‐up. Br J Dermatol. 2017;177:924‐935.
Kaser DJ, Reichman DE, Laufer MR. Prevention of vulvovaginal sequelae in stevens‐johnson syndrome and toxic epidermal necrolysis. Rev Obstet Gynecol. 2011;4:81‐85.
Lebargy F, Wolkenstein P, Gisselbrecht M, et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med. 1997;23:1237‐1244.
De Prost N, Ingen‐Housz‐Oro S, Duong TA, et al. Bacteremia in Stevens‐Johnson syndrome and toxic epidermal necrolysis: Epidemiology, risk factors, and predictive value of skin cultures. Medicine. 2010;89(1):28‐36.
Beck A, Cooney R, Gamelli RL, Mosier MJ. Predicting Mechanical Ventilation and Mortality: Early and Late Indicators in Steven‐Johnson Syndrome and Toxic Epidermal Necrolysis. J Burn Care Res. 2016;37:e47‐e55.
Brauer A, Perl T, Quintel M. [Perioperative thermal management]. Anaesthesist. 2006;55:1321‐1339;quiz 1340.
Bruggen MC, Le ST, Walsh S, et al. Supportive care in the acute phase of Stevens‐Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphi‐based consensus. Br J Dermatol. 2021;185:616‐626.
Chanques G, Viel E, Constantin JM, et al. The measurement of pain in intensive care unit: comparison of 5 self‐report intensity scales. Pain. 2010;151:711‐721.
Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin (DGAI), Deutsche Interdisziplinäre Vereinigung für Intensiv‐ und Notfallmedizin (DIVI). S3‐Leitlinie Analgesie, Sedierung und Delirmanagement in der Intensivmedizin (DAS‐Leitlinie), Version 5.0. 2021; AWMF‐Registernummer: 001/012.
Diao M, Thapa C, Ran X, et al. A retrospective analysis of infections and antibiotic treatment in patients with Stevens‐Johnson syndrome and toxic epidermal necrolysis. J Dermatolog Treat. 2020;31:61‐65.
Deutsche Gesellschaft für Ernährungsmedizin e.V. (DGEM). S2k‐Leitlinie Klinische Ernährung in der Intensivmedizin, Version 2.0. 2018;AWMF‐Register‐Nr. 073‐004.
Jochum F, Krohn K, Kohl M, et al. Parenterale Ernährung in der Kinder‐und Jugendmedizin. Aktuel Ernährungsmed. 2014;39:233‐255.
Shiga S, Cartotto R. What are the fluid requirements in toxic epidermal necrolysis? J Burn Care Res. 2010;31:100‐104.
Hefez L, Zaghbib K, Sbidian E, et al. Post‐traumatic stress disorder in Stevens‐Johnson syndrome and toxic epidermal necrolysis: prevalence and risk factors. A prospective study of 31 patients. Br J Dermatol. 2019;180:1206‐1213.
O'Reilly P, Meskell P, Whelan B, et al. Psychotherapeutic interventions for burns patients and the potential use with Stevens‐Johnson syndrome and toxic epidermal necrolysis patients: A systematic integrative review. PLoS One. 2022;17:e0270424.
Butt TF, Cox AR, Lewis H, Ferner RE. Patient experiences of serious adverse drug reactions and their attitudes to medicines: a qualitative study of survivors of Stevens‐Johnson syndrome and toxic epidermal necrolysis in the UK. Drug Saf. 2011;34:319‐328.
Kuijper EC, French LE, Tensen CP, et al. Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN). J Eur Acad Dermatol Venereol. 2020;34:1957‐1971.
Agarwal V, O'Neill PJ, Cotton BA, et al. Prevalence and risk factors for development of delirium in burn intensive care unit patients. J Burn Care Res. 2010;31:706‐715.
Wenham T, Pittard A. Intensive care unit environment. Continuing Education in Anaesthesia Critical Care & Pain. 2009;9:178‐183.
Barbaud A, Collet E, Milpied B, et al. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol. 2013;168:555‐562.
Wolkenstein P, Chosidow O, Flechet ML, et al. Patch testing in severe cutaneous adverse drug reactions, including Stevens‐Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis. 1996;35:234‐236.
Pushker N, Gorimanipalli B, Sharma N, et al. Mucous membrane grafting (fibrin glue vs. suture) for lid margin pathologies in Stevens‐Johnson syndrome: randomized comparative study. Eye (Basingstoke). 2021;35(7):1985‐1992.
Chronopoulos A, Mockenhaupt M, Pleyer U. Okuläre Beteiligung bei Stevens‐Johnson‐Syndrom und toxisch epidermaler Nekrolyse. Der Ophthalmologe. 2021;118:519‐532.

Auteurs

Maren Paulmann (M)

Department of Dermatology and Venereology, Center for the Documentation of Severe Skin Reactions (dZh), University Medical Center Freiburg, Freiburg, Germany.

Ruben Heuer (R)

Department of Dermatology, Venereology and Allergology, Division of Evidence Based Medicine (dEBM), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Thorsten Annecke (T)

Department of Anesthesiology and Critical Care Medicine, Merheim Medical Center, Hospital of Witten/Herdecke University, Cologne, Germany.

Björn Behr (B)

Department of Plastic and Hand Surgery, Burn Center, Sarcoma Center, BG University Hospital Bergmannsheil, Ruhr University Bochum, Bochum, Germany.
Department of Plastic, Reconstructive & Aesthetic Surgery, KEM Evangelische Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung Essen-Huttrop, Essen, Germany.

Katharina Boch (K)

Department of Dermatology, Allergology and Venereology, University Hospital Schleswig-Holstein, Campus Lübeck, Germany.

Anja M Boos (AM)

Department of Plastic Surgery, Hand Surgery - Burn Center, University Hospital RWTH Aachen, Aachen, Germany.

Knut Brockow (K)

Department of Dermatology and Allergology, University Medical Center, Technical University of Munich, Munich, Germany.

Lars E French (LE)

Department of Dermatology and Allergy, Ludwig Maximilian University Munich, Munich, Germany.

Jochen Gille (J)

Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, St. Georg Hospital Leipzig, Leipzig, Germany.

Verena Gundlach (V)

Heart Center Niederrhein - Department of Cardiac Surgery and Cardiovascular Surgery, Helios Hospital Krefeld, Krefeld, Germany.

Bernd Hartmann (B)

Department of Plastic Surgery, Burn Centre, BG Klinikum Unfallkrankenhaus Berlin, Berlin, Germany.

Peter Höger (P)

Department of Pediatric Dermatology/Allergology, Catholic Children's Hospital Wilhelmstift Hamburg, Hamburg, Germany.

Silke C Hofmann (SC)

Center for Dermatology, Allergology and Dermatosurgery, Helios University Hospital Wuppertal, University of Witten/Herdecke, Wuppertal, Germany.

Tobias Klein (T)

Department of Pediatric Surgery and Pediatric Urology, Children's Hospital of Cologne, Cologne, Germany.

Marcus Lehnhardt (M)

Department of Plastic and Hand Surgery, Burn Center, Sarcoma Center, BG University Hospital Bergmannsheil, Ruhr University Bochum, Bochum, Germany.

Yvonne Liß (Y)

Office Dr. Jana Filser, Mannheim, Germany.

Philip Maier (P)

Eye Center, University Medical Center Freiburg, Freiburg, Germany.

Philipp Mandel (P)

Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany.

Nicos Marathovouniotis (N)

Department of Pediatric Surgery and Pediatric Urology, Children's Hospital of Cologne, Cologne, Germany.

Finnja Marlok (F)

Patient Representative, Untermünkheim, Germany.

Hans Mittelviefhaus (H)

Department of Dermatology and Allergy, Ludwig Maximilian University Munich, Munich, Germany.

Uwe Pleyer (U)

Department of Ophthalmology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.

Marie Pradeau (M)

Department of Dermatology, Venereology and Allergology, Division of Evidence Based Medicine (dEBM), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Katharina Rall (K)

Department of Women's Health, University Hospital Tübingen, Tübingen, Germany.

Siegbert Rieg (S)

Department of Medicine II - Gastroenterology, Hepatology, Endocrinology and Infectiology, University Medical Center Freiburg, Freiburg, Germany.

Heike Rittner (H)

Department of Anesthesiology, Intensive Care, Emergency and Pain Medicine, Centre for Interdisciplinary Pain Medicine, University Hospital Würzburg, Würzburg, Germany.

Frank Sander (F)

Department of Plastic Surgery, Burn Centre, BG Klinikum Unfallkrankenhaus Berlin, Berlin, Germany.

Stefan Schnitzler (S)

Department of Surgical Intensive Care and Intermediate Care, University Hospital RWTH Aachen, Aachen, Germany.

Christina Schut (C)

Institute of Medical Psychology, Justus Liebig University Gießen, Gießen, Germany.

Annette Stolle (A)

Andreas Wentzensen Research Institute, BG Hospital Ludwigshafen, Ludwigshafen, Germany.

Artem Vorobyev (A)

Department of Dermatology, Allergology and Venereology, University Hospital Schleswig-Holstein, Campus Lübeck, Germany.

Bettina Wedi (B)

Department of Dermatology, Allergology and Venereology, Hannover Medical School, Hannover, Germany.

Johannes Weiss (J)

Department of Dermatology and Allergology, University Hospital Ulm, Ulm, Germany.

Maximilian Zepp (M)

Patient Representative, Kaiserslautern, Germany.

Mirjana Ziemer (M)

Department of Dermatology, Venereology and Allergology, University Hospital Leipzig, Leipzig, Germany.

Maja Mockenhaupt (M)

Department of Dermatology and Venereology, Center for the Documentation of Severe Skin Reactions (dZh), University Medical Center Freiburg, Freiburg, Germany.

Alexander Nast (A)

Department of Dermatology, Venereology and Allergology, Division of Evidence Based Medicine (dEBM), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Classifications MeSH